Among patients with rheumatoid arthritis receiving stable DMARD treatment, long-term glucocorticoid use is associated with a dose-dependent increase in the risk for serious infection, with a “small but significant” risk even at the lowest doses, researchers report.
Treatment with the IL-6 receptor inhibitor sarilumab is associated with a greater improvement in glycemic control than conventional DMARDs or adalimumab among patients with comorbid rheumatoid arthritis and diabetes, indicate findings from a post-hoc analysis.
Patients with early rheumatoid arthritis who report higher HAQ-measured disability after taking DMARDs for a year are at greater risk for all-cause mortality than those who report lower disability scores, indicate findings from the Canadian Early Arthritis Cohort.
The authors of a systematic review report that DMARD treatment does not seem to have a detrimental impact on fertility in patients with rheumatoid arthritis, but limited evidence means that more research is needed.
Anti-carbamylated vimentin antibodies may be associated with treatment response and structural damage progression among patients with rheumatoid arthritis, shows a post-hoc analysis of data from the phase 3 RA-BEGIN trial.
Patients with rheumatic and musculoskeletal diseases are almost twice as likely to adhere to COVID-19 social distancing regulations as the general population, suggests research conducted in the Netherlands.
A real-world comparison of biologic, targeted synthetic, and conventional DMARDs indicates that TNF inhibitors and abatacept are associated with a reduction in CVD risk in patients with rheumatoid arthritis.
Women are less likely than men to hold senior academic rheumatology positions and are under-represented as senior authors of published research articles, suggest findings from two studies published in Arthritis & Rheumatology.
Treatment with the IL-6 receptor inhibitor tocilizumab may be associated with a reduction in time on mechanical ventilation, shorter hospital stay, and decreased mortality risk among patients with severe COVID-19, suggest findings from three studies.
Canakinumab monotherapy tapering, either through dose reduction or dose interval prolongation, is feasible in children with systemic juvenile idiopathic arthritis who achieve clinical remission, study findings indicate.
Among people with inflammatory rheumatic diseases and SARS-CoV-2 infection, having a connective tissue disease, but not inflammatory arthritis, is associated with an increased risk for severe COVID-19, Spanish researchers report.
The authors of a systematic review and meta-analysis have identified a number of clinical and laboratory features that should be assessed when investigating patients with suspected giant cell arteritis.
Denosumab may reduce the risk for mTSS worsening among patients with rheumatoid arthritis who have risk factors for radiographic progression, particularly those with anti-cyclic citrullinated peptide antibody positivity, researchers report.